Printer Friendly

Xytronyx Inc. reports fiscal 1995 third- quarter results.

SAN DIEGO--(BUSINESS WIRE)--Feb. 10, 1995--Xytronyx Inc. (ASE:XYX) Friday announced results for the third quarter ended Dec. 31, 1994.

Revenues for the third quarter ended Dec. 31, 1994, were $51,000, compared with $282,000 for the same period of the prior year. Net results were a loss of $913,000, or 17 cents per share, compared with a loss of $856,000, or 21 cents per share, for the third quarter of the prior year.

Xytronyx also noted that the current quarter results include $86,000 in costs incurred relating to the U.S. clinical trials of the Periodontal Tissue Monitor kit.

Revenues for the nine months ended Dec. 31, 1994, were $1,152,000, compared with $405,000 for the same period of the prior year. Net results were a loss of $2,503,000, or 50 cents per share, compared with a loss of $2,629,000, or 66 cents per share, for the same period of the prior year.

The increase in revenues is related to an agreement with Coors Brewing Co. (Coors) for use of Xytronyx's Kephra reversible color change technology in a summer 1994 promotion by Coors.

Xytronyx also noted that product development expenses for the current nine month period includes approximately $500,000 in costs incurred relating to the U.S. clinical trials of the Periodontal Tissue Monitor kit.

Xytronyx is engaged in the development and commercialization of products based on biotechnological research primarily in the areas of medicine, dentistry and veterinary medicine. -0-
 Xytronyx Inc. and Subsidiary (a development stage company)
 Consolidated Financial Data
 (unaudited)


 Three Months Ended Nine Months Ended
 Dec. 31, Dec. 31,
 1994 1993 1994 1993
 -------------------------------------------
REVENUES
 Product sales $ 9,021 $262,611 $612,744 $323,518
 License fees and
 royalties -- -- 330,000 --
 Contract research -- -- 99,151 --
 Option agreements -- -- -- 26,500
 Interest and other 42,444 19,016 110,542 54,944
 Total revenues 51,465 281,627 1,152,437 404,962


COST AND EXPENSES
 Cost of product
 sales 45,255 217,630 394,449 373,249
 Product development 341,289 255,572 1,483,821 644,369
 General and
 administrative 344,668 573,938 1,187,224 1,614,406
 Business development
 and marketing 219,339 69,588 548,402 341,586
 Interest and other 13,888 20,751 41,812 60,007
 Total costs and
 expenses 964,439 1,137,479 3,655,708 3,033,617


Net loss $(912,974) $(855,852)$(2,503,271) $(2,628,655)


Net loss per
 share of common
 stock (17 cents) (21 cents) (50 cents) (66 cents)


Weighted average
 shares
 outstanding 5,263,029 4,155,097 5,055,211 3,983,783
-0-


 Dec. 31, 1994 March 31, 1994
Cash, cash equivalents and
 short-term investments $3,022,429 $4,504,010
Total assets 3,628,587 5,168,231
Long-term liabilities 36,364 69,880
Stockholders' equity 3,135,506 3,941,774


CONTACT: Xytronyx Inc., San Diego

Dale A. Sander, 619/546-1114
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 10, 1995
Words:497
Previous Article:Canon U.S.A. launches powerful lineup of 19 new products at Photo Marketing Show.
Next Article:Pacer Technology Reports Mixed Results For 2nd Quarter and 6 Months of 1995.
Topics:


Related Articles
Xytronyx Reports Second Quarter 1995 Results.
Xytronyx Inc. reports fiscal-year 1995 results.
Xytronyx Inc. extends standstill agreement regarding the Xytronyx Periodontal Tissue Monitor.
Xytronyx Inc. reports fiscal 1996 first- quarter results.
Xytronyx Inc. reports fiscal 1996 third-quarter results.
Xytronyx Inc. announces signing of agreement for option to acquire Binary Therapeutics Inc.
Xytronyx Inc. reports fiscal year 1996 results.
Xytronyx Inc. announces approval of agreement by majority of shareholders of Binary Therapeutics Inc.
Xytronyx Inc. announces private placement.
Xytronyx Inc. completes $10 million private placement and announces other significant events.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters